Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Trial was underpowered
| The first 150 words of the full text of this article appear below. |
EDITOR
The paper reporting the trial to improve follow up in general
practice of patients with coronary heart disease after discharge from
hospital is unduly pessimistic.1 At least one of the
authors (Mant) has been in this situation before.
Mant worked on the OXCHECK study, which found comparable differences of less than 5% between control and intervention groups and in which a strategy identifying patients at high risk was abandoned in favour of targeting those with established disease at yet higher risk.2 It was left to Field et al to show that the OXCHECK study was successful and that the incremental addition of assessment of multiple risk factors to a pre-existing programme targeting smoking and blood pressure was a cost effective way of improving risk factors. 3 4
The failure to show substantial differences in outcomes in both Jolly
et al's trial and the OXCHECK study has resulted from flaws in